Explore more publications!
Technology Digest Bermuda
Got News to Share?

Technology Digest Bermuda: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Technology Digest Bermuda.

February 2026

Mo Tu We Th Fr Sa Su
1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28

March 2026

Mo Tu We Th Fr Sa Su
1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31

April 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30

Press releases published on April 22, 2026

Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)
Apr. 22, 2026

Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

Indeterminate GlobeNewswire
The Elmet Group Co. Announces Pricing of Upsized Initial Public Offering
Apr. 22, 2026

The Elmet Group Co. Announces Pricing of Upsized Initial Public Offering

Indeterminate GlobeNewswire
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria
Apr. 22, 2026

Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria

Indeterminate GlobeNewswire
Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé aux États-Unis comme étant le premier médicament biologique pour les jeunes enfants atteints d’urticaire chronique spontanée non contrôlée
Apr. 22, 2026

Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé aux États-Unis comme étant le premier médicament biologique pour les jeunes enfants atteints d’urticaire chronique spontanée non contrôlée

Indeterminate GlobeNewswire
 nCino Announces Nick Edwards as Managing Director for APAC
Apr. 22, 2026

 nCino Announces Nick Edwards as Managing Director for APAC

Indeterminate GlobeNewswire
Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)
Apr. 22, 2026

Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)

Indeterminate GlobeNewswire
Kneat to Announce 2026 First-Quarter Financial Results May 13, 2026
Apr. 22, 2026

Kneat to Announce 2026 First-Quarter Financial Results May 13, 2026

Indeterminate GlobeNewswire
George Medicines: New England Journal of Medicine publishes global stroke outcomes trial that demonstrated reduction of risk for recurrent stroke by almost 40% with GMRx2 in patients with previous intracerebral hemorrhage
Apr. 22, 2026

George Medicines: New England Journal of Medicine publishes global stroke outcomes trial that demonstrated reduction of risk for recurrent stroke by almost 40% with GMRx2 in patients with previous intracerebral hemorrhage

Indeterminate GlobeNewswire
GigaCloud Technology Inc Announces Planned Retirement of Head of Brand Center
Apr. 22, 2026

GigaCloud Technology Inc Announces Planned Retirement of Head of Brand Center

Indeterminate GlobeNewswire
Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
Apr. 22, 2026

Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

Indeterminate GlobeNewswire
BIO-key Receives Notice of Non-Compliance from Nasdaq Related to Delay of its Form 10-K Filing
Apr. 22, 2026

BIO-key Receives Notice of Non-Compliance from Nasdaq Related to Delay of its Form 10-K Filing

Indeterminate GlobeNewswire
Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Apr. 22, 2026

Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Altimmune Announces Proposed Underwritten Public Offering of Securities
Apr. 22, 2026

Altimmune Announces Proposed Underwritten Public Offering of Securities

Indeterminate GlobeNewswire
Alzai Health Corp. Files Final Prospectus in Connection With Initial Public Offering
Apr. 22, 2026

Alzai Health Corp. Files Final Prospectus in Connection With Initial Public Offering

Indeterminate GlobeNewswire
IBEX Limited to Announce Third Quarter 2026 Financial Results on May 6, 2026
Apr. 22, 2026

IBEX Limited to Announce Third Quarter 2026 Financial Results on May 6, 2026

Indeterminate GlobeNewswire
Silo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, Qwikagents
Apr. 22, 2026

Silo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, Qwikagents

Indeterminate GlobeNewswire
Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026
Apr. 22, 2026

Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026

Indeterminate GlobeNewswire
Abivax to Present Data on Obefazimod at Digestive Disease Week®
Apr. 22, 2026

Abivax to Present Data on Obefazimod at Digestive Disease Week®

Indeterminate GlobeNewswire
Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Apr. 22, 2026

Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026
Apr. 22, 2026

BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions